Please login to the form below

Not currently logged in
Email:
Password:

DDR

This page shows the latest DDR news and features for those working in and with pharma, biotech and healthcare.

AZ showcases data for next-generation PARP inhibitor AZD5305

AZ showcases data for next-generation PARP inhibitor AZD5305

PARP inhibitors work to prevent cancer cells from repairing, by blocking PARP enzymes which help to repair DNA damage in cells – also known as the DNA damage response (DDR) pathway. ... Like PARP inhibitors, the inhibition of WEE1 is focused on the DDR

Latest news

  • Merck KGaA signs deal with Artios Pharma potentially worth up to $860m Merck KGaA signs deal with Artios Pharma potentially worth up to $860m

    Artios’ management team are experts in the DNA damage response (DDR) field and were involved in developing olaparib, the first DDR inhibitor, now on its way to becoming a blockbuster for ... This collaboration further strengthens our leadership and

  • Evotec spins off cancer tech into new Breakpoint company Evotec spins off cancer tech into new Breakpoint company

    Will challenge AstraZeneca and others in DNA damage response. German biotech Evotec has decided to bundle its cancer therapeutic programmes focused on DNA damage response (DDR) into a new spin-off ... Spinning the programmes into a stand-alone company

  • UK biotech Artios Pharma appoints new medical director UK biotech Artios Pharma appoints new medical director

    He will focus on helping Artios progress its pipeline of first-in-class DNA damage response (DDR) therapies. ... The company is developing a next generation of DDR therapies, targeting mechanisms such as the down-regulation or loss of certain DNA repair

  • AZ to address Imfinzi setback, but sees potential with Tagrisso AZ to address Imfinzi setback, but sees potential with Tagrisso

    Baselga also confirmed that it will "highlight an exciting new phase of scientific discovery", in the form of a new wave of DNA Damage Response (DDR) targets. ... Moving its DDR pipeline beyond PARP inhibition, AZ will share data on a potent and

  • DNA damage specialists Artios Pharma raises $84m DNA damage specialists Artios Pharma raises $84m

    We are delighted to work with the management team in building a world class DDR targeted oncology company.”. ... investors for their continued support, which will help us develop and deliver our exciting DDR targeted therapies to cancer patients.

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Cutting through the noise: CRISPR Cutting through the noise: CRISPR

    is furthering work in DNA damage response (DDR), a key platform in oncology.

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    She says understanding about the role of a host of other DDR pathways and mechanisms is deepening – and AstraZeneca is leading the industry. ... So that’s the rationale behind combinations of DDR agents with immuno-oncology.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Artios Pharma appoints science strategy VP Artios Pharma appoints science strategy VP

    Dr Boulton joins the newly-launched oncology specialist to lead the development of the company's two lead DNA Damage Response (DDR) programmes as well as assisting the business development team ... first-in-class DDR programmes and establish Artios as a

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...